

Review

Open Access

Trophoblast-uterine interactions at implantation

John D Aplin*^{1,2} and Susan J Kimber²

Address: ¹Academic Unit of Obstetrics and Gynaecology, University of Manchester, St Mary's Hospital, Manchester M13 0JH, UK and ²School of Biological Sciences, University of Manchester, Manchester M13 9PT, UK

Email: John D Aplin* - john.aplin@man.ac.uk; Susan J Kimber - sue.kimber@man.ac.uk

* Corresponding author

Published: 05 July 2004

Received: 24 January 2004

Accepted: 05 July 2004

Reproductive Biology and Endocrinology 2004, **2**:48 doi:10.1186/1477-7827-2-48

This article is available from: <http://www.rbej.com/content/2/1/48>

© 2004 Aplin and Kimber; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Implantation of the embryo in the uterus is a critical and complex event and its failure is widely considered an impediment to improved success in assisted reproduction. Depending on whether placentation is invasive or superficial (epitheliochorial), the embryo may interact transiently or undergo a prolonged adhesive interaction with the uterine epithelium. Numerous candidate interactions have been identified, and there is good progress on identifying gene networks required for early placentation. However no molecular mechanisms for the epithelial phase are yet firmly established in any species. It is noteworthy that gene ablation in mice has so far failed to identify obligatory initial molecular events.

Milestones of implantation

Implantation of the embryo into the uterine wall is a requirement for developmental progression beyond the blastocyst stage *in vivo*. Its obvious significance to species survival implies the need for a robust mechanism that can survive suboptimal conditions of e.g. nutrition or infection. Since problems in pregnancy frequently originate in the pre and peri-implantation period, understanding the mechanisms of implantation will facilitate the discovery of therapies applicable at a time when both embryo and endometrium are at their most accessible.

The human embryo implants about 7–11 days after the LH peak [1,2]. Many human conceptuses fail to implant because of genetic or metabolic abnormalities [3,4], but poor uterine receptivity has been widely proposed as another cause of implantation failure [5–8]. In rat and mouse, the implantation window lasts for only about 24 h at day 4–5 of pregnancy [9]. Unimplanted blastocysts recovered by flushing and transferred to receptive mothers give normal pregnancies, and blastocysts transferred to pre-receptive uteri implant according to the maternal

schedule [10,11], indicating that receptivity is largely maternally controlled. However, the molecular basis of this phenomenon is not understood. In domestic livestock species with non-invasive (epitheliochorial or syncytioepitheliochorial) implantation, a pre-attachment phase of 8–15 days is followed by a more prolonged period of apposition and attachment; as a result, these species offer clear advantages for the elucidation of cell adhesion and intercellular communication mechanisms.

Hormonal requirements for implantation have been defined by replacing embryos in ovariectomised mice or rats under various regimes of exogenous steroid. The required sequence is estrogen (E) followed by progesterone (P), and then E plus P. The E/P-primed uterus supports the survival of blastocysts within the lumen for a considerable time, as long as daily P is administered (delayed implantation), and a dose of E during P stimulation is an absolute necessity for implantation to occur. This corresponds to the nidatory E pulse in natural cycles. Experimentally, the size of the E dose affects the duration of the receptive phase [8]. The post-receptive uterus is

hostile to unimplanted embryos, which degenerate. While rats and mice are useful model systems, some key features are clearly not relevant to human where, for example, the influence of a post-implantation uterine cavity on unimplanted conceptuses is irrelevant since menstruation is imminent [12]. The human receptive phase probably ends when corpus luteum rescue is no longer feasible.

Pre-implantation endocrine patterns during human conception cycles resemble closely those seen in non-conception cycles, though circulating luteal phase E and P levels are rather higher in the former [13]. Endometrial preparation in artificial cycles does not depend on the precise replication of natural cycles [6], and it remains unclear whether luteal phase E production is required for implantation in women. The high level of E in ovarian hyperstimulation cycles has an adverse effect on mouse endometrial receptivity [8], but may also affect the embryo directly with inhibition of implantation, as observed *in vitro* [14]. If mouse embryos are transferred to one oviduct at the pronuclear stage, and simultaneously into the contralateral oviduct at the 8 cell stage, both implant, though in the former case implantation is delayed by at least one day. Developmental synchronisation has occurred by the neural plate stage [15]. This experiment suggests that an embryo-maternal dialogue influences the timing of the receptive phase.

Gland cell secretions and the early embryo-maternal dialogue

The early human maternal-fetal interface is characterised by the blockage (by trophoblast) of maternal spiral arteries and no blood flow through the intervillous space, so the system is very hypoxic. In contrast to the arteries, maternal glands open into the intervillous space, and glycogen and other glandular secretory substances (histiotroph) are taken up by trophoblast [16]. In the mouse, ablation of the hypoxia inducible gene Arnt/HIF1 α leads to abnormal placental development and pregnancy failure, suggesting a role for hypoxia-regulated genes. In sheep lacking uterine glands, embryos develop to the hatched blastocyst stage, but do not progress, probably because of a failure of attachment [17]. This suggests that glandular histiotroph may contribute to implantation [18].

Calcitonin is an endometrial gland cell secretory product expressed in response to P [19] that is important for pregnancy outcome in rats, as indicated by a reduction in implantation rates if maternal expression is blocked using antisense oligonucleotide [20]. Calcitonin acts on the pre-implantation embryo by binding a G-protein-coupled receptor, triggering an increase in intracellular calcium, activation of adenyl cyclase and expression of the

fibronectin receptor, integrin $\alpha 5\beta 1$ [21], a part of the activation step (see below).

Mouse uterine glands secrete leukaemia inhibitory factor (LIF) which is essential for implantation [22]. It binds to receptors in the luminal epithelium (LE), triggering stat-3 activation only on the day of implantation [23]. Together with embryo-derived signals, LIF, acting via the LE initiates a signalling cascade that leads to stromal decidualisation [24]. However LIF inhibits decidualisation of stromal cells *in vitro* perhaps suggesting a restraining role away from the implantation site [25]. Various molecular abnormalities are associated with the absence of LIF during the receptive phase, such as lack of expression of Cox-2 and EGF family cytokines including heparin-binding epidermal growth factor (HB-EGF [26]) as well as the secreted protein coch-5b2 [27]. The prostaglandins/prostacyclins, products of Cox enzyme activity, have been considered important instruments in initiating decidualisation. Indeed when wild type embryos were transferred to the uteri of Cox-2 null C57Bl/6J/129 mice a decidualisation reaction was not observed and they were reported not to implant [28,29]. However in another study on these mice it was shown that implantation occurs normally but decidualisation is delayed [30]. Moreover it appears that, in Cox-2 null CD-1 mice, compensatory upregulation of Cox-1 occurs at the implantation site, maintaining prostacyclin levels and allowing at least some implantation reaction although this is delayed [29]. These observations make evident the importance of genetic background [31].

It is clear that the embryo signals its presence to the maternal system but few changes in decidualising stroma have been identified solely in response to the embryo, as distinct from being products of decidual differentiation. Although interferon (an important embryonic signal to the mother in ruminants) is not produced by murine blastocysts, an interferon-stimulated gene (Isg15) has recently been shown to be expressed in murine decidua, as in other species, in an embryo-dependent manner [32].

Embryo growth, hatching and activation

Metabolic changes occur during pre-implantation development, from the relative quiescence of the cleavage stages to the metabolically more active blastocyst with its high rate of glucose uptake [33]. Replacement of blastocysts has been advocated in human assisted reproduction programs, since it allows preimplantation genetic investigation to be carried out after removal of one or two cells at the cleavage stages [34,3]. A two-stage culture protocol has been adopted with somewhat richer nutrient provision during the morula to blastocyst phase [35]. When culture is carried out continuously in nutrient-poor medium, some embryos develop to blastocysts, but implantation rates are reduced. Human blastocyst

morphology varies greatly, but karyotypically abnormal embryos can develop into apparently normal blastocysts. Just as with the karyotype, the metabolic characteristics of morphologically normal blastocysts vary greatly [36]. Thus the ability of an embryo to develop to this stage does not guarantee successful pregnancy. However, morphology of karyotypically normal blastocysts is likely to be a good indicator of pregnancy outcome [37]. Blastocyst, as opposed to early cleavage, transfer allows synchrony between embryo and tract environment, and allows selection of competent embryos to facilitate single embryo transfer.

Growth factors secreted in response to E and P from both oviductal and endometrial epithelium contribute to the milieu of the developing embryo. Numerous factors, including insulin, LIF, leptin, heparin-binding epidermal growth factor (HB-EGF) granulocyte-macrophage colony stimulating factor (GM-CSF) and insulin like growth factor 1 (IGF-1) have been shown to increase either the rate of embryo development to blastocyst stage or blastocyst cell number in culture (Figure; reviewed in: [38,39]. Studies in genetically modified mice have also demonstrated a clear role for pre-implantation signalling between mother and embryo. GM-CSF is produced by the uterine epithelium and stimulated by E [40] while the embryo expresses a GM-CSF receptor [41]. Mice genetically altered to lack GM-CSF produce blastocysts with fewer cells in the ICM, and these give rise to small pups. The defect can be rescued by culturing null preimplantation embryos in medium supplemented with GM-CSF before replacement [41]. In cow, GM-CSF localises to the apical LE surface both before and after embryo attachment, and is upregulated by interferon- τ produced by the embryo [42]. Human embryos express GM-CSF receptors [43,44] and so can respond to this ligand.

Before an embryo can attach to the uterine surface, it must hatch from the zona pellucida. Two serine proteases, ISP1 and ISP2 (implantation serine proteases 1 and 2), have been implicated in hatching. ISP1 is produced by the embryo, while ISP2 is produced by uterine glands. These enzymes may also be required for local proteolysis of maternal tissue as part of the process of invasion [45].

In addition to metabolic activation and hatching, the blastocyst must be activated to attach to maternal luminal epithelium (LE), at least in the mouse model of delayed implantation. In the presence of P, dormant blastocysts are closely apposed to the uterine epithelium but do not attach. E treatment produces a receptive state in the uterus mediated by interaction of estradiol-17 β with its nuclear receptor. In contrast, the embryo is activated (as evidenced by induced EGF binding) by a catecholesterogen, 4-hydroxyestradiol-17 β , produced locally in the

endometrium as a metabolite of estradiol [46-48]. Activation of blastocysts is unaffected by blocking nuclear ER signalling, but prevented by inhibition of prostaglandin (PG) synthesis, adenyl cyclase or protein kinase A (PKA). This suggests a pathway in which PG stimulates cAMP synthesis to mediate activation through PKA. One important manifestation of activation is the early translocation of integrins $\alpha 5\beta 1$ and $\alpha 4\beta 1$ to the apical surface of abembryonic TE in mice [49,21,50]. Integrin $\alpha 5\beta 1$ -fibronectin engagement induces calmodulin-mediated calcium transients in the blastocyst, suggesting outside-in signalling [51]. Moreover, fibronectin induces trafficking of $\alpha IIb\beta 3$ and appears to be involved in the strengthening of interaction between trophoblast and uterine fibronectin as trophoblast invasion commences [52].

After attachment to the epithelial surface, embryos of interstitially implanting species invade the underlying stroma. Embryonic genes are emerging which have essential functions in the early post-epithelial phases of implantation; their ablation gives a phenotype that resembles implantation failure. Mouse embryos genetically modified to lack integrin $\beta 1$ fail to complete implantation, probably because of an inability to bind the maternal subepithelial extracellular matrix [53]. Embryos lacking the Ron/STK receptor tyrosine kinase, a member of the c-met family which is expressed in trophoblast, fail at similarly early stages. Its ligand HGFL is contemporaneously expressed in the uterus. However, HGFL-null animals implant normally, suggesting the existence of another ligand [54]. Others have reviewed genes required for early development of the embryo/placenta [55,56].

Hormonal influences on the endometrium at implantation

The classical model of E acting on endometrial cells to stimulate P receptor expression, with P then inducing differentiation and preparation for implantation, is an oversimplification, because receptor expression varies in a complex fashion in different cell types and tissue compartments in the uterus [57]. The basal endometrium, from which post-menstrual regeneration occurs in human, differs from the superficial or functional layer [58]. These differences arise at least in part because of site-specific paracrine interactions between the epithelium and stroma in regulating endometrial function, as established elegantly in studies of mice lacking E receptors [59]. Epithelial proliferation in response to E does not occur in receptor (ER α)-negative stroma recombined with wild type epithelium, but occurs normally if the receptor is present in the stroma and not the epithelium. However, the control of expression of epithelial secretory proteins such as mouse lactoferrin relies on the presence of receptor in both stromal and epithelial compartments. The same principles apply to human endometrium; for

example, in secretory phase, P stimulates PR-bearing stromal cells to produce transforming growth factor β (TGF β), and this in turn suppresses production of matrix metalloproteinase 7 (MMP7) by the epithelium in a P-independent step. At the end of the cycle, P levels fall and MMP7 contributes to extracellular matrix (ECM) remodelling during menstruation [60-62].

Although ER α is thought to be the main receptor mediating E effects in the uterus, both mouse and human endometrium express lower levels of ER β . Ablation of ER β in mice compromises reproductive function [63] and current evidence suggests it may act to modulate ER α . Similarly, P receptor splice variants A and B function as distinct transcription factors [64]. The localisation of ER β (but not PR) to uterine NK cells [65] which colonise the endometrium in late secretory phase, serves to emphasise that careful delineation of the cell types in which receptors are expressed is just as important as monitoring their cycle dependency.

Endocrine mediators other than E and P also play a role. Endometrial cells express the androgen receptor AR [66], the luteinising hormone receptor LHR[67], the gonadotrophin-releasing hormone receptor [68], the prolactin receptor [69], the leptin receptor Ob-R [70] and the relaxin receptors LGR 7 and 8 [71]. AR can be expressed in stromal as well as epithelial cells but its functions in endometrial physiology have not been defined. Human chorionic gonadotrophin (hCG) is a ligand for LHR, raising the possibility of a paracrine interaction with the embryo. Mice genetically altered to lack LHR develop a very small uterus [72]. After steroid replacement, the uterus returns to a normal size and histological features are fairly normal, though fewer glands are present. Embryos transferred into these mice however produce no pregnancies, and at present the explanation for this infertility is not clear. There is evidence that hCG may advance endometrial differentiation [73] and act as an autocrine regulator of trophoblast [74]. Parathyroid-related hormone produced by endometrium induces primary and secondary mouse trophoblast differentiation to giant cells *in vitro* [75] El-Hashash and Kimber unpublished. Prolactin, produced by human stromal cells undergoing decidualisation, activates receptors on uterine large granulated lymphocytes [69] potentially influencing their role in post-implantation uterine function.

The endometrial transcriptome

Recently, the search for elusive markers of endometrial receptivity has included differential display, subtractive hybridisation and differential microarray screening to compare the endometrial transcriptome in receptive and non-receptive states. It is conceptually useful in these studies to distinguish genes (such as tyrosine kinase fam-

ily receptors or transcription factors) that may directly or indirectly influence the downstream expression of a set of target genes from those (such as integrins) directly involved in cell interactions. Since implantation seems to occur in a range of endometrial 'settings' (i.e. variations in gene expression), it will be necessary to ask whether expression of 'master genes' with the ability to change these settings is altered in infertile women.

Several studies [76-79] have compared human mid secretory phase endometrium with non-receptive stages (either early secretory or proliferative). In one study, patient-to-patient variation was eliminated by sampling tissue from the same individual at two different times of the same cycle [79]. Consistent patterns of 'receptive state' gene expression have not yet emerged. Some known genes – osteopontin is a notable example [80] – exhibit alterations consistent with previous data (see below). New genes will require functional study, for example IGFBP-rP1/mac 25 [81]. Certain genes are conspicuous by their absence (indicating lack of detected up or down regulation): notably the transcription factor HoxA10 and the growth factor LIF, both essential for implantation in mouse as revealed by gene ablation, and integrin β 3, a subunit of the epithelial and vascular receptor $\alpha\beta\beta$ 3 which is regulated by Hoxa10 [82] and a candidate for mediating embryo attachment to the uterine epithelium (see below).

Animal models can offer better-controlled approaches. Reese and colleagues [83] identified mouse genes expression of which is altered in *both* implantation vs inter-implantation site *and* delayed implantation uterus (P only) vs tissue that had been E-treated to terminate the delay. Distinct sets of genes are upregulated or repressed in inter-site tissue vs the implantation site, with numerous functional categories represented. Nearly half the genes repressed by E or at implantation sites have immune-related functions. Connexins 26 and 43 and amphiregulin are notably elevated in implantation-receptive RNA isolates, as is nexin-1, a serine protease inhibitor expressed in uterine stromal cells [84]. Decysin, a member of the ADAM family that is present in the uterine stroma, is down-regulated at the implantation site and shows altered expression in the prolactin receptor-null mouse, which exhibits implantation failure that is partially overcome by exogenous P treatment [85]. In a study comparing luminal epithelial genes from implantation site and interimplantation site there was notable upregulation of genes involved with the extracellular matrix and its remodeling or associated with calcium for function at the implantation site [86].

Differential display of cDNA species present in implantation and inter-implantation sites on day 4.5 of pregnancy in the mouse has identified differential expression of

several proteins. This includes an increase in transcripts encoding the calcium binding protein calbindin-d9k (CABP-d9k) in the luminal epithelium at the interimplantation site [87,88]. Downregulation of CABP-d9k at the implantation site [89] or after blastocyst transfer [90] suggests precise spatial and temporal regulation of calcium-mediated signalling, or calcium availability, may be critical during implantation as also indicated by the importance of calcitonin (see above). Subtractive hybridisation of endometrial libraries has identified other interesting leads in rhesus monkey [91] and rabbit [92].

Mouse maternal implantation genes regulated by P have been identified by transcriptomic analysis comparing receptive phase uterus with or without an implantation-blocking dose of the anti-progestin RU486. P-dependence was subsequently confirmed by re-assay in the P receptor knock-out (PRKO) mouse [93]. Alterations are observed in several genes of known importance including Hoxa11 [94,95], amphiregulin [83,96], laminin α 2 [97] and spermidine synthase [83], validating the approach. In vivo uterine administration of antisense oligonucleotide to Irg1, a gene identified in the implantation phase LE, blocked implantation [93]. Other novel genes are now candidates for functional analysis.

The cellular and molecular events of embryo attachment

In all species there is an initial interaction, no matter how short-lived, between the outer TE cell surface and the apical LE. It is likely that a cascade of adhesion events is initiated [98-100] (see Fig). In turn this leads to signalling events, targets for which are located in both epithelial and subjacent stromal cells. Other than the most immediate responses at implantation, the stromal changes lie outside the scope of this review.

A change in epithelial cell organisation at the time of implantation seems to occur generally across the range of mammals, irrespective of differences in control mechanisms and subsequent trophoblast behaviour [101]. In mice, attachment to the maternal epithelial surface is followed by apoptosis of the epithelial cells, allowing trophoblast direct access to the underlying basement membrane and stroma [102,103]. In human, it is thought that intrusive penetration of the epithelium is followed by its displacement, but there is also evidence that epithelial apoptosis may occur [104].

Epithelial junctions

Early postovulatory and receptive LE have very different phenotypes. Gap junction distribution and complexity changes in the LE lateral membrane in several species at receptivity. Connexins 26 and 43 are regulated in LE and stroma during the human menstrual cycle [105]. Con-

nexin 26 is expressed in the rodent implantation chamber epithelium, and CX26 and 43 in stroma, and these are tightly regulated by ovarian steroids including progesterone-mediated suppression [106,107]. Alterations in LE cell-cell interactions are also indicated by changes in the apico-lateral distribution of cell surface molecules, for instance integrin α 6 distribution changes from basal to both lateral and basal during the secretory phase [108]. In mouse, E-induced E-cadherin degradation leads to reduced LE adhesion on d4.5 of pregnancy [109]. Lateral cadherins have also been reported to relocate to the apical LE surface at the time of implantation in rat [110]. In women, changes in E-cadherin mRNA probably reflect E-dependent down regulation [111]. Desmosomal proteins are downregulated and redistributed along the lateral cell surfaces in murine LE [112] and the density of desmosomes similarly decreases in human at the expected time of implantation [113]. LE cell polarity becomes less marked with appearance of latero-basal markers in the apical membrane [114]. The cells are flatter and microvilli are replaced by bulbous protrusions (uterodomes) in many species [115,116]. In women, uterodomes appear in LE cells about 5–6 days after ovulation [117-119] correlating with the expected receptive phase. Studies using repeated biopsy demonstrated that uterodomes have a lifetime of less than 48 h. Three human blastocysts co-cultured with endometrial epithelial cells were reported to attach where clusters of cells bearing uterodomes were present in the cell layer [118].

Epithelial glycobiology and attachment

In common with other epithelial surfaces, the uterine LE contains an apical glycocalyx which allows the diffusion of small molecules but inhibits cell adhesion [99], and protects the upper tract from infectious agents. The cell surface mucin MUC1 is a component [120-123]. In mice and rats, Muc1 is downregulated precisely at the time of implantation under the control of maternal steroids [124]. Consistent with this, it emerges as a highly upregulated (6-fold) gene at day 4 in pregnant mice that have been treated at day 3 with a single dose of RU486 [93]. There is evidence that another surface mucin, Muc4, is also downregulated in rats [125]. Loss of Muc1 also occurs in pig and sheep [126,127], while in contrast, humans express high levels throughout the receptive phase, though the pattern of its glycosylation changes [120,123]. Indeed, mucin-associated oligosaccharides are useful markers of endometrial differentiation [123] and pathology [128,129].

Experimental studies of human implantation in which embryos hatch and attach to endometrial epithelial cells in monolayer culture have shown that Muc1 disappears from a small area of cells that surround the attached embryo [130,131]. The mechanism of removal is not

established, though it has been shown that a proteolytic cleavage event catalysed by ADAM17/TACE can mediate release from the surface of cultured cells, and that ADAM17 is expressed in the LE [132].

Local remodelling of the glycocalyx implies an earlier interaction (apposition) that positions the hatched blastocyst at an area of LE where implantation will subsequently take place. Carbohydrate-lectin binding has been suggested to mediate initial weak attachment in a parallel with the leukocyte-endothelial interaction that occurs at inflammatory sites [115,133,134]. The epithelial H-type-1 antigen Fu α 1-2Gal β 1-3GlcNAc β 1-4 is expressed in LE in several species [133,134]. Its involvement in implantation has been suggested in the mouse, where attachment to endometrial epithelial cells is inhibited by free oligosaccharide in vitro (reviewed in [116]). However, other evidence suggests that H-type-1 interaction is not essential to implantation or can be compensated in its absence: implantation is normal in mice carrying a deletion of *Fut2*, the fucosyltransferase required for H-type1 biosynthesis [135]. Furthermore uterine injection of antibody to H-type-1 fails to block implantation [136]. From antibody inhibition in vivo, the possible involvement of the Le-y carbohydrate antigen (Fu α 1-2Gal β 1-4[Fu α 1-3]GlcNAc β 1-) was suggested [136,137]. This is present on the blastocyst surface in mouse and on LE in mouse and human [138,139]. Since Le-y glycolipid has been demonstrated to bind H-type-1 and-2 chain glycolipids, Le-y on the blastocyst could interact with H-type-1 on apical LE [140]. However, the *Fut2* enzyme is again required to produce ligand.

The selectin ligand sialyl Le-x is present on human LE where it is carried by MUC-1 [98]. It increases in the mouse LE during the receptive period [141]. There is uncertainty as to the expression of selectins on human and mouse preimplantation embryos [142-144]. In sheep, the mucin GlyCAM-1, a ligand for L-selectin in lymph node endothelium, is expressed both by LE and trophectoderm during the initial interaction period [145]. In homozygotic mutant mice null for each of the three selectins, and in mice lacking two or all three selectins, embryonic development, implantation and pregnancy appear normal [146-148].

Heparan sulphate has been implicated in several implantation models. The blastocyst expresses syndecan-1, a transmembrane heparan sulphate proteoglycan (HSPG), but little can be detected at the outer surface of TE [148] and its absence after gene deletion does not appear to influence fertility [150]. Perlecan, the major basement membrane HSPG, surrounds the blastocyst after hatching and expression of the mRNA and protein correlates with acquisition of attachment competence [151,152]. Again,

perlecan-null embryos show no implantation phenotype, being indistinguishable from wild type embryos until d9.5 [153]. A truncated form of heparin-binding EGF-like growth factor (HB-EGF) is induced in the LE by the embryo and could also interact with HSPG [154]. HB-EGF appears in epithelial cells immediately adjacent to the implanting embryo just 6-7 hours before the embryo attaches. In delayed implantation, HB-EGF appears only after the nidatory E stimulus is given. HB-EGF has been suggested to play two different roles: in addition to accelerating embryo development, it has a membrane-bound variant that can mediate intercellular attachment by binding to erb-B4 as well as to heparan sulphate proteoglycan on the mouse blastocyst [155,156]. HB-EGF-null and erb-B4-null mice develop heart problems [157,158]. Erb B4 nulls die early in gestation while the majority of HB-EGF nulls die before weaning. However, surviving HB-EGF/-adult females are fertile, and fertile erb-B4 nulls can be produced after cardiomyocyte-specific rescue of the heart defect.

Epithelial adhesion molecules

Trophinin is a membrane glycoprotein that forms complexes with the proteins bystin and tastin, and was identified as a candidate mediator of embryonic attachment by the demonstration of its involvement in adhesion of human trophoblastic and endometrial cell lines [159,160]. Early secretory phase human endometrial epithelium expresses trophinin and tastin at the apical surface, and at the macaque implantation site, trophinin expression is observed at the apposed apical surfaces of TE and LE. However, murine implanting blastocysts do not show detectable levels of trophinin protein, and although there is a partial embryonic lethality associated with ablation of the gene, this appears to be a post-implantation phenomenon [161].

Basigin (EMMPRIN, CD147) is an immunoglobulin superfamily member with putative roles in cell interaction, MMP activation and orientation of ion transporters in the plasma membrane. It is expressed in the LE [162] and also in decidual cells [163]. Igakura et al [164] showed that transfer of wild type blastocysts into basigin-null females resulted in a very low rate of implantation. Menstrual cycle-dependent molecular variants have been observed in human endometrium [165].

Integrin $\alpha v\beta 3$ has been suggested to be important in embryo attachment in human, mouse, rabbit and farm animals [5,18]. The $\beta 3$ subunit exhibits regulated expression with the heterodimer $\alpha v\beta 3$ present in human epithelium only from about day 19. $\alpha v\beta 3$ is also present on the external surface of the expanded blastocyst [142,166]. Its ligands include fibronectin, vitronectin, tenascin, osteopontin, thrombospondin and possibly laminin (see




Figure 1
Diagrammatic representation of the series of interactions between the trophectoderm/trophoblast (TE) and luminal epithelium (LE) and subjacent stroma. Potential roles of cell adhesion molecules at each stage are indicated. 1) Pre-receptive polarised endometrial epithelium with desmosomes distributed along lateral LE cell surfaces and non-adhesive apical cell surface; 2) Receptive endometrium and initial embryo attachment: reorganisation of lateral LE adhesion complexes accompanies apical carbohydrate ligand engagement to tether blastocyst; integrins and cell-bound HB-EGF now become available for TE-binding; 3) Stabilisation of initial attachment by αv or other integrin-mediated adhesion involving bridging ligands shown; other components are also probably functional; 4) Potential signalling through cell adhesion ligand-receptor interaction including calmodulin and calcium.

[98,134]). Neutralising antibodies to either αv or $\beta 3$ integrin injected into mouse uterus, although producing some apparent effect, failed to induce a statistically significant reduction in implantation sites. However echistatin, which inactivates $\alpha v\beta 3$ integrin as well as $\alpha iib\beta 3$ and $\alpha 5\beta 1$ [167], and an RGD-containing peptide, did produce a significant reduction in implantation sites [168]. This may suggest that other integrins which bind to the RGD sites in ligands play a redundant or overlapping role in implantation.

Osteopontin is a secretory product of endometrial glands, is associated with the apical surface of luminal epithelial cells, and is directly regulated by P, with maximal abundance in secretory phase [80,169]. Osteopontin can bind CD44 (which is present on LE [170] as well as several integrins ($\alpha v\beta 5$, $\alpha v\beta 1$, $\alpha 4\beta 1$, $\alpha 5\beta 1$ and $\alpha 8\beta 1$). Mice with ablated CD44, which is also a receptor for hyaluronan, do not show obviously impaired fertility [171]. Osteopontin is strongly detected at the apical surface of human endometrial secretory phase glands [169]. It could act as a bridging ligand for TE-LE interactions, but osteopontin-null and osteopontin/vitronectin double knockout mice are fertile [172].

The largest subfamily of integrins shares the $\beta 1$ subunit. This has been localised, along with $\alpha 1$, $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$ and $\alpha 9$ to the lateral and basal surfaces, but not the apical surface, of endometrial epithelial cells (reviewed in [99,134]). Pregnancy fails in mice lacking integrin $\beta 1$ at a stage that closely follows epithelial attachment, perhaps reflecting a defect in interaction with the stromal ECM [53]. Expression of integrin $\alpha 4\beta 1$ is highest in human GE between mid proliferative and mid secretory phases. In mouse, in addition to its presence on the surface of activated blastocysts, $\alpha 4\beta 1$ is expressed on the basal LE surface and stromal cells in response to E. Intrauterine injection of monoclonal antibody to $\alpha 4$ reduced implantation rates substantially though it is not clear what interaction was targeted [50].

Conclusions

Since implantation is unique to mammals we cannot extrapolate from other common model organisms in the search for possible targets and mechanisms. Nonetheless our understanding of the process of implantation has grown slowly in the last decade. Some of the interactions that have been recognised as important are shown schematically in the Figure. Current in vitro models reproduce only small stages in the implantation process. Knockout strategies have revealed the essential role of certain soluble mediators (e.g. LIF) and the contribution to reproductive efficiency made by others (e.g. GM-CSF), but it is notable that the crucial structural or attachment molecules have not been identified. The importance of implan-

tation to the survival of mammals means that there may exist multiple parallel mechanisms. Thus either compensatory effects may be invoked or impairment of reproductive efficiency (rather than system failure) following gene ablation. Microarray technology has begun to be used in the search for key implantation mechanisms, but differential screening approaches will identify only transcriptionally-regulated products, with post-transcriptionally- and post-translationally-controlled components likely to remain undiscovered through current research strategies. Proteomics may offer a useful complement to existing approaches.

References

- Berg PA, Navot D: **The impact of embryonic development and endometrial maturity on the timing of implantation.** *Fertil Steril* 1992, **58**:537-42.
- Aplin JD: **Implantation.** In: *Encyclopedia of Hormones* Edited by: Simpson E. San Diego, Academic Press; 2003:289-297.
- Pellicer A, Rubio C, Vidal F, Minguez Y, Gimenez C, Egoscue J, Remohi J, Simon C: **In vitro fertilization plus preimplantation genetic diagnosis in patients with recurrent miscarriage: an analysis of chromosome abnormalities in human preimplantation embryos.** *Fertil Steril* 1999, **71**:1033-1039.
- Quenby S, Vince G, Farquharson R, Aplin J: **Recurrent miscarriage: a defect in nature's quality control?** *Hum Reprod* 2002, **17**:1959-1963.
- Lessey BA: **Uterine factors in implantation.** In: *The Endometrium* Edited by: Glasser SR, Aplin JD, Giudice L, Tabibzadeh S. London, Taylor and Francis; 2002:208-228.
- Chang PL, Sauer MV: **The oocyte donation model: lessons on endometrial receptivity.** In: *The Endometrium* Edited by: Glasser SR, Aplin JD, Giudice L, Tabibzadeh S. London, Taylor and Francis; 2002:495-509.
- Sharkey AM, Smith SK: **The endometrium as a cause of implantation failure.** *Best Pract Res Clin Obstet Gynaecol* 2003, **17**:289-307.
- Ma WG, Song H, Das SK, Paria BC, Dey SK: **Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation.** *Proc Natl Acad Sci USA* 2003, **100**:2963-2968.
- Psychoyos A: **Uterine receptivity for nidation.** *Ann N Y Acad Sci* 1986, **476**:36-39.
- McLaren A, Michie A: **Studies on the transfer of fertilised mouse eggs to uterine foster mothers I. Factors affecting the implantation and survival of native and transferred eggs.** *J Exp Biol* 1955, **33**:394-416.
- Dickmann Z, Noyes RW: **The fate of ova transferred into the uterus of the rat.** *J Reprod Fert* 1960, **1**:197-212.
- Wilcox AJ, Baird DD, Weinberg CR: **Time of implantation of the conceptus and loss of pregnancy.** *N Engl J Med* 1999, **340**:1796-1799.
- Baird DD, Wilcox AJ, Weinberg CR, Kamel F, McConnaughey DR, Musey PI, Collins DC: **Preimplantation hormonal differences between the conception and non-conception menstrual cycles of 32 normal women.** *Hum Reprod* 1997, **12**:2607-2613.
- Valbuena D, Martin J, de Pablo JL, Remohi J, Pellicer A, Simón C: **Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo.** *Fertil Steril* 2001, **76**:962-968.
- Ueda O, Keigo Yorozu K, Kamada N, Jishage K-i, Kawase Y, Toyoda Y, Suzuki H: **Possible expansion of "window of implantation" in pseudopregnant mice: Time of Implantation of embryos at different stages of development transferred into the same recipient.** *Biol Reprod* 2003, **69**:1085-1090.
- Burton GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E: **Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy.** *J Clin Endocrinol Metab* 2002, **87**:2954-2959.
- Gray CA, Burghardt RC, Johnson GA, Bazer FW, Spencer TE: **Evidence that absence of endometrial gland secretions in uter-**

- ine gland knockout ewes compromises conceptus survival and elongation.** *Reproduction* 2002, **124**:289-300.
18. Burghardt RC, Johnson GA, Jaeger LA, Ka H, Garlow JE, Spencer TE, Bazer FW: **Integrins and extracellular matrix proteins at the maternal-fetal interface in domestic animals.** *Cells Tissues Organs* 2002, **172**:202-217.
 19. Kumar S, Zhu LJ, Polihronis M, Cameron ST, Baird DT, Schatz F, Dua A, Ying YK, Bagchi MK, Bagchi IC: **Progesterone induces calcitonin gene expression in human endometrium within the putative window of implantation.** *J Clin Endocrinol Metab* 1998, **83**:4443-4450.
 20. Zhu LJ, Bagchi MK, Bagchi IC: **Attenuation of calcitonin gene expression in pregnant rat uterus leads to a block in embryonic implantation.** *Endocrinology* 1998, **139**:330-339.
 21. Wang J, Rout UK, Bagchi IC, Armant DR: **Expression of calcitonin receptors in mouse preimplantation embryos and their function in the regulation of blastocyst differentiation by calcitonin.** *Development* 1998, **125**:4293-302.
 22. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, Abbon-danzo SJ: **Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor.** *Nature* 1992, **359**:76-79.
 23. Cheng JG, Chen JR, Hernandez L, Alvord WG, Stewart CL: **Dual control of LIF expression and LIF receptor function regulate Stat3 activation at the onset of uterine receptivity and embryo implantation.** *Proc Natl Acad Sci USA* 2001, **98**:8680-8685.
 24. Chen JR, Cheng JG, Shatzer T, Sewell L, Hernandez L, Stewart CL: **Leukemia inhibitory factor can substitute for nidatory E and is essential to inducing a receptive uterus for implantation but is not essential for subsequent embryogenesis.** *Endocrinology* 2000, **141**:4365-4372.
 25. Fouladi Nashta AA, Andreu CV, Nijjar N, Heath JK, Kimber SJ: **Role of Leukemia Inhibitory factor (LIF) in decidualisation of murine uterine stromal cells in vitro.** *J Endocrinol* 2004, **181**:477-492.
 26. Song H, Lim H, Das SJ, Paria BC, Dey SK: **Dysregulation of EGF family of growth factors and Cox-2 in the uterus during the preattachment and attachment reactions of the blastocyst with the luminal epithelium correlates with implantation failure in LIF deficient mice.** *Mol Endocrinol* 2000, **14**:1147-1161.
 27. Rodriguez CI, Cheng G Jr, Liu L, Stewart CL: **Cochlin, a secreted VWA domain containing factor, is regulated by LIF in the uterus at the time of implantation.** *Endocrinology* 2004, **145**:1410-1418.
 28. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK: **Multiple female reproductive failures in cyclooxygenase 2-deficient mice.** *Cell* 1997, **91**:197-208.
 29. Wang H, Ma WG, Tejada L, Zhang H, Morrow JD, Das SK, Dey SK: **Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory upregulation of cyclooxygenase-1 is a function of genetic background.** *J Biol Chem* 2004, **279**:10649-10658.
 30. Cheng JG, Stewart CL: **Loss of cyclooxygenase-2 retards decidual growth but does not inhibit embryo implantation or development to term.** *Biol Reprod* 2003, **68**:401-404.
 31. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ, Magnuson T: **Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype.** *Science* 1995, **269**:230-234.
 32. Austin KJ, Bany E, Belden L, Rempel LA, Cross JC, Hansen TR: **Interferon-stimulated gene-15 (Isg15) expression is up-regulated in the mouse uterus in response to the implanting conceptus.** *Endocrinology* 2003, **144**:3107-3113.
 33. Leese HJ: **Quiet please, do not disturb: a hypothesis of embryo metabolism and viability.** *Bioessays* 2002, **24**:845-849.
 34. Handyside AH, Lesko JG, Tarin JJ, Winston RM, Hughes MR: **Birth of a normal girl after in vitro fertilisation and preimplantation diagnostic testing for cystic fibrosis.** *N Engl J Med* 1992, **327**:905-909.
 35. Gardner DK, Lane ML, Schoolcraft WB: **Physiology and culture of human blastocyst.** *J Reprod Immunol* 2002, **55**:85-100.
 36. Houghton FD, Hawkhead JA, Humpherson PG, Hogg JE, Balen AH, Rutherford AJ, Leese HJ: **Non-invasive amino acid turnover predicts human embryo developmental capacity.** *Hum Reprod* 2002, **17**:999-1005.
 37. Gardner DK, Sakkas D: **Assessment of embryo viability: the ability to select embryo for transfer- a review.** *Placenta* 2003, **24**:S5-S12.
 38. Diaz-Cueto L, Gerton GL: **The influence of growth factors on the development of preimplantation embryos.** *Arch Med Res* 2001, **32**:619-626.
 39. Hardy K, Spanos S: **Growth factor expression and function in the human and mouse preimplantation embryo.** *J Endocrinol* 2002, **172**:221-236.
 40. Robertson SA, Mayrhofer G, Seemark RF: **Ovarian steroid hormones regulate granulocyte-macrophage colony-stimulating factor synthesis by uterine epithelial cells in the mouse.** *Biol Reprod* 1996, **54**:183-196.
 41. Robertson SA, Sjöblom C, Jasper MJ, Norman RJ, Seemark RF: **Granulocyte-macrophage colony-stimulating factor promotes glucose transport and blastomere viability in murine preimplantation embryos.** *Biol Reprod* 2001, **64**:1206-1215.
 42. Emond V, MacLaren LA, Kimmings S, Arosh JA, Fortier MA, Lambert RD: **Expression of cyclooxygenase-2 and granulocyte-macrophage colony-stimulating factor in the endometrial epithelium of the cow is up-regulated during early pregnancy and in response to intrauterine infusions of interferon-tau.** *Biol Reprod* 2004, **70**:54-64.
 43. Sjöblom C, Wiklund M, Robertson SA: **Granulocyte-macrophage colony-stimulating factor promotes human blastocyst development in vitro.** *Hum Reprod* 1999, **14**:3069-3076.
 44. Sjöblom C, Wiklund M, Robertson SA: **Granulocyte-macrophage colony-stimulating factor (GM-CSF) acts independently of the beta common subunit of the GM-CSF receptor to prevent inner cell mass apoptosis in human embryos.** *Biol Reprod* 2002, **67**:1817-1823.
 45. O'Sullivan CM, Rancourt SL, Liu SY, Rancourt DE: **A novel murine tryptase involved in blastocyst hatching and outgrowth.** *Reproduction* 2001, **122**:61-71.
 46. Paria BC, Huet-Hudson YM, Dey SK: **Blastocyst's state of activity determines the 'window' of implantation' in the receptive mouse uterus.** *Proc Natl Acad Sci USA* 1993, **90**:10159-10162.
 47. Paria BC, Lim H, Wang XN, Liehr J, Das SK, Dey SK: **Coordination of differential effects of primary estrogen and catecholestrogen on two distinct targets mediates embryo implantation in the mouse.** *Endocrinology* 1998, **139**:5235-5246.
 48. Paria BC, Lim H, Das SK, Reese J, Dey SK: **Molecular signalling in uterine receptivity for implantation.** *Seminars in Cell Dev Biol* 2000, **11**:67-76.
 49. Schultz JF, Mayerik L, Rout UK, Armant DR: **Integrin trafficking regulates adhesion to fibronectin during differentiation of mouse peri-implantation blastocysts.** *Dev Genet* 1997, **21**:31-43.
 50. Basak S, Dhar R, Das C: **Steroids modulate the expression of alpha4 integrin in mouse blastocysts and uterus during implantation.** *Biol Reprod* 2002, **66**:1784-1789.
 51. Wang J, Mayerik L, Armant DR: **Integrin signalling regulates blastocyst adhesion to fibronectin at implantation: intracellular calcium transients and vesicle trafficking in primary trophoblast cells.** *Devel Biol* 2002, **245**:270-279.
 52. Rout UK, Wang J, Paria BC, Armant DR: **$\alpha 5\beta 1$, $\alpha V\beta 3$ and the platelet associated integrin $\alpha IIb\beta 3$ coordinately regulate adhesion and migration of differentiating mouse trophoblast cells.** *Dev Biol* 2004, **268**:135-151.
 53. Stephens LE, Sutherland AE, Klimanskaya IV, Andriew A, Meneses J, Pedersen RA, Damsky CH: **Deletion of $\beta 1$ integrins in mice results in inner cell mass failure and peri-implantation lethality.** *Genes Dev* 1995, **9**:1883-1895.
 54. Muraoka RS, Sun WY, Colbert MC, Waltz SE, Witte DP, Degen JL, Friezner Degen SJ: **The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse.** *J Clin Invest* 1999, **103**:1277-1285.
 55. Cross JC: **Genetic insights into trophoblast differentiation and placental morphogenesis.** *Seminars Cell Dev Biol* 2000, **11**:99-113.
 56. Rossant J, Cross JC: **Placental development: lessons from mouse mutants.** *Nature Reviews Genetics* 2001, **2**:538-548.
 57. Tibbetts TA, Mendoza-Meneses M, O'Malley BW, Conneely OM: **Mutual and intercompartmental regulation of estrogen receptor and progesterone receptor expression in the mouse uterus.** *Biol Reprod* 1998, **59**:1143-1152.

58. Mote PA, Balleine RL, McGowan EM, Clarke CL: **Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma.** *Hum Reprod* 2001, **15**(Suppl 3):48-56.
59. Cooke PS, Buchanan DL, Kurita T, Lubahn DB, Cunha GR: **Role of stromal-epithelial interactions in hormonal responses of the uterus.** In: *The Endometrium* Edited by: Glasser SR, Aplin JD, Giudice L, Tabibzadeh S. London, Taylor and Francis; 2002:151-166.
60. Osteen KG, Rodgers WH, Gaire M, Hargrove JT, Gorstein F, Matrisian LM: **Stromal-epithelial interaction mediates steroid regulation of metalloproteinase expression in human endometrium.** *Proc Natl Acad Sci USA* 1994, **91**:10129-10133.
61. Bruner KL, Rodgers WH, Gold LI, Korc M, Hargrove JT, Matrisian LM, Osteen KG: **Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium.** *Proc Natl Acad Sci USA* 1995, **92**:7362-7366.
62. Aplin JD: **Endometrial extracellular matrix.** In: *The Endometrium* Edited by: Glasser SR, Aplin JD, Giudice L, Tabibzadeh S. London, Taylor and Francis; 2002:294-307.
63. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M: **Effect of single and compound knockouts of E receptors α (ER α) and β (ER β) on mouse reproductive phenotypes.** *Development* 2000, **127**:4277-4291.
64. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW: **Reproductive functions of progesterone receptors.** *Recent Prog Horm Res* 2002, **57**:339-55.
65. Henderson TA, Saunders PT, Moffett-King A, Groome NP, Critchley HO: **Steroid receptor expression in uterine natural killer cells.** *J Clin Endocrinol Metab* 2003, **88**:440-449.
66. Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO, Baird DT, Brenner RM: **Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium.** *J Clin Endocrinol Metab* 2001, **86**:2668-2679.
67. Bukovsky A, Indrapichate K, Fujiwara H, Cekanova M, Ayala ME, Dominguez R, Caulde MR, Wimalseera J, Elder RF, Copas P, Foster JS, Fernando RI, Henley DC, Upadhyaya NB: **Multiple luteinizing hormone receptor (LHR) protein variants, interspecies reactivity of anti-LHR mAb clone 3B5, subcellular localization of LHR in human placenta, pelvic floor and brain, and possible role for LHR in the development of abnormal pregnancy, pelvic floor disorders and Alzheimer's disease.** *Reprod Biol Endocrinol* 2003, **1**:46.
68. Huang H-Y, Raga F, Wen Y, Kruessel JS, Soong Y-K, Polan ML: **IL-1 β regulation of GnRH RNA in cultured endometrial stromal cells.** *Fert Steril* 2003, **79**:399-406.
69. Gubbay O, Critchley HO, Bowen JM, King A, Jabbour HN: **Prolactin induces ERK phosphorylation in epithelial and CD56(+) natural killer cells of the human endometrium.** *J Clin Endocrinol Metab* 2002, **87**:2329-2335.
70. Gonzalez RR, Leary K, Petrozza JC, Leavis PC: **Leptin regulation of the interleukin-1 system in human endometrial cells.** *Mol Hum Reprod* 2003, **9**:151-158.
71. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ: **Activation of orphan receptors by the hormone relaxin.** *Science* 2002, **295**(5555):671-674.
72. Rao CV, Lei ZM: **Consequences of targeted inactivation of LH receptors.** *Mol Cell Endocrinol* 2002, **187**:57-67.
73. Fanchin R, Peltier E, Frydman R, de Ziegler D: **Human chorionic gonadotropin: does it affect human endometrial morphology in vivo?** *Semin Reprod Med* 2001, **19**:31-35.
74. Yang M, Lei ZM, Rao Ch V: **The central role of human chorionic gonadotrophin in the formation of human placental syncytium.** *Endocrinology* 2003, **144**:1108-1120.
75. Nowak RA, Haimovici F, Biggers JD, Erbach GT: **Transforming growth factor-beta stimulates mouse blastocyst outgrowth through a mechanism involving parathyroid hormone-related protein.** *Biol Reprod* 1999, **60**:85-93.
76. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN, Lessey BA, Giudice LC: **Global gene profiling in human endometrium during the window of implantation.** *Endocrinology* 2002, **143**:2119-2128.
77. Carson DD, Lagow E, Thatthiah A, Al-Shami R, Farach-Carson MC, Vernon M, Yuan L, Fritz MA, Lessey B: **Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening.** *Mol Hum Reprod* 2002, **8**:871-879.
78. Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith SK: **Determination of the transcript profile of human endometrium.** *Mol Hum Reprod* 2003, **9**:19-33.
79. Riesewijk A, Martin J, van Os R, Horcajadas JA, Polman J, Pellicer A, Mosselman S, Simón C: **Gene expression profiling of human endometrial receptivity on days LH+2 versus LH+7 by microarray technology.** *Mol Hum Reprod* 2003, **9**:253-264.
80. Johnson GA, Burghardt RC, Bazer FW, Spencer TE: **Osteopontin: roles in implantation and placentation.** *Biol Reprod* 2003, **69**:1458-1471.
81. Dominguez F, Avila S, Cervero A, Martin J, Pellicer A, Castrillo JL, Simon C: **A combined approach for gene discovery identifies insulin-like growth factor-binding protein-related protein 1 as a new gene implicated in human endometrial receptivity.** *J Clin Endocrinol Metab* 2003, **88**:1849-1857.
82. Daftary GS, Troy PJ, Bagot CN, Young SL, Taylor HS: **Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells.** *Mol Endocrinol* 2002, **16**:571-579.
83. Reese J, Das SK, Paria BC, Lim H, Song H, Matsumoto H, Knudtson KL, DuBois RN, Dey SK: **Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation.** *J Biol Chem* 2001, **276**:44137-44145.
84. Kim NK, Choi MJ, Chung HM, Sohn TJ, Hwang SG, Oh D, Lee HH, Lee YH, Ko JJ: **Increased expression and localization of a serine protease inhibitor, protease nexin-1 (PN-1), in the ovary and uterus during implantation in rat.** *Thromb Res* 2001, **103**:135-142.
85. Baran N, Kelly PA, Binart N: **Decysin, a new member of the metalloproteinase family, is regulated by prolactin and steroids during mouse pregnancy.** *Biol Reprod* 2003, **68**:1787-1792.
86. Yoon S-J, Choi D-H, Lee W-S, Cha K-Y, Kim A-N, Lee K-A: **A molecular basis for embryo apposition at the luminal epithelium.** *Mol Cell Endocrinol* 2004, **219**:95-104.
87. Nie GY, Li Y, Wang J, Minoura H, Findlay JK, Salamonsen LA: **Complex regulation of calcium-binding protein D9k (calbindin-D(9k)) in the mouse uterus during early pregnancy and at the site of embryo implantation.** *Biol Reprod* 2000, **62**:27-36.
88. Salamonsen LA, Nie G, Findlay JK: **Newly identified endometrial genes of importance for implantation.** *J Reprod Immunol* 2002, **53**:215-225.
89. Nie GY, Li Y, Batten L, Griffiths B, Wang J, Findlay JK, Salamonsen LA: **Uterine expression of alternatively spliced mRNAs of mouse splicing factor SC35 during early pregnancy.** *Mol Hum Reprod* 2000, **6**:1131-1139.
90. Tasumi K, Higuchi T, Fujiwara H, Nakayama T, Itoh K, Mori T, Fujii S, Fujita J: **Expression of calcium binding protein D-9k messenger RNA in the mouse uterine endometrium during implantation.** *Mol Human Reprod* 1999, **5**:153-161.
91. Okulicz WC, Ace CI: **Temporal regulation of gene expression during the expected window of receptivity in the rhesus monkey endometrium.** *Biol Reprod* 2003, **69**:1593-1599.
92. Melner MH, Ducharme NA, Brash AR, Winfrey VP, Olson GE: **Differential expression of genes in the endometrium at implantation: upregulation of a novel member of the E2 class of ubiquitin-conjugating enzymes.** *Biol Reprod* 2004, **70**:406-414.
93. Cheon YP, Li Q, Xu X, DeMayo FJ, Bagchi IC, Bagchi MK: **A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation.** *Mol Endocrinol* 2002, **16**:2853-2871.
94. Gendron RL, Paradis H, Hsieh-Li HM, Lee DW, Potter SS, Markoff E: **Abnormal uterine stromal and glandular function associated with maternal reproductive defects in Hox-a11 null mice.** *Biol Reprod* 1997, **56**:1097-1105.
95. Hsieh-Li HM, Witte DP, Weinstein M, Branford W, Li H, Small K, Potter SS: **Hoxa11 structure, extensive antisense transcription and function in male and female fertility.** *Development* 1995, **121**:1373-1385.
96. Paria BC, Reese J, Das SK, Dey SK: **Deciphering the cross-talk of implantation: advances and challenges.** *Science* 2002, **296**:2185-2188.
97. Church HJ, Vicovac LM, Williams JD, Hey NA, Aplin JD: **Laminins 2 and 4 are expressed by human decidual cells.** *Lab Invest* 1996, **74**:21-32.

98. Hey NA, Aplin JD: **Sialyl Lewis x and Sialyl Lewis a are expressed by human endometrial MUC1.** *Glycoconjugate J* 1996, **13**:769-779.
99. Aplin JD: **Adhesion molecules in implantation.** *Reviews of Reproduction* 1997, **2**:84-93.
100. Kimber SJ, Spanswick C: **The adhesion cascade.** In: *The Endometrium* Edited by: Glasser SR, Aplin JD, Giudice L, Tabibzadeh S. London, Taylor and Francis; 2002:229-248.
101. Thie M, Denker HW: **In vitro studies on endometrial adhesiveness for trophoblast: cellular dynamics in uterine epithelial cells.** *Cells Tissues Organs* 2002, **172**:237-252.
102. Parr EL, Parr MB: **Epithelial cell death during rodent embryo implantation.** In *Blastocyst Implantation* Edited by: Yoshinago K. Boston USA :Serono Symposia USA Adams Publ Group; 1989:105-115.
103. Kanijo T, Rajabi MR, Mizunuma H, Ibuki Y: **Biochemical evidence for autocrine/paracrine regulation of apoptosis in cultured uterine epithelial cells during mouse embryo implantation in vitro.** *Mol Hum Reprod* 1998, **4**:990-998.
104. Galán A, O'Connor E, Valbuena , Herrer R, Remohí J, Pampfer S, Pellicer A, Simon C: **The human blastocyst regulates endometrial epithelial apoptosis in embryonic adhesion.** *Biol Reprod* 2000, **63**:430-439.
105. Classen-Linke JE, Kusche M, Beier HM, Traub O, Grunmmer R, Winterhager E: **Expression of gap junction connexins in the human endometrium throughout the menstrual cycle.** *Hum Reprod* 1995, **10**:2666-2670.
106. Winterhager E, Grümmmer R, Jahn K, Willecke K, Traub O: **Spatial and Temporal expression of connexin26 and connexin43 in rat endometrium during trophoblast invasion.** *Devel Biol* 1993, **157**:399-409.
107. Grümmmer R, Traub O, Winterhager E: **Gap junction connexin genes cx26 cx43 are differentially regulated by ovarian steroid hormones in rat endometrium.** *Endocrinology* 1999, **140**:2509-2516.
108. Albers A, Thie M, Hohn HP, Denker HW: **Differential expression and localization of integrins and CD44 in the membrane domains of human uterine epithelial cell during the menstrual cycle.** *Acta Anat* 1995, **153**:12-21.
109. Potter SW, Gaze G, Morris JE: **Estradiol induces E-cadherin degradation in mouse uterine epithelium during the estrous cycle and early pregnancy.** *J Cell Physiol* 1996, **169**:1-14.
110. Hyland RA, Shaw TJ, Png FY, Murphy CR: **Pan-cadherin concentrates apically in uterine epithelial cells during uterine closure in the rat.** *Acta Histochem* 1998, **100**:75-81.
111. Fujimoto J, Ichigo S, Hori M, Tamaya T: **Alteration of E-cadherin alpha- and beta-catenin mRNA expression in human uterine endometrium during the menstrual cycle.** *Gynecol Endocrinol* 1996, **10**:187-191.
112. Illingworth IM, Kiska I, Bagley S, Ireland GW, Garrod DW, Kimber SJ: **Desmosomes are reduced in the mouse uterine luminal epithelium during the pre-implantation period of pregnancy: A mechanism for facilitating implantation.** *Biol Reprod* 2000, **63**:1764-1773.
113. Sarani SA, Ghaffari-Novin M, Warren MA, Dockery P, Cooke ID: **Morphological evidence for the 'implantation window' in human luminal endometrium.** *Hum Reprod* 1999, **14**:3101-3106.
114. Thie M, Fuchs P, Butz S, Sieckmann F, Hoschutzky H, Kemler R, Denker HW: **Adhesiveness of the apical surface of uterine epithelial cells: the role of junctional complex integrity.** *Eur J Cell Biol* 1996, **70**:221-232.
115. Psychoyos A: **Endocrine control of egg implantation.** In: *Handbook of Physiology* Edited by: Greep RO, Astwood EG, Geiger SR. Washington DC American Physiological Soc; 1973:187-215.
116. Kimber S, White S, Cook A, Illingworth I: **The initiation of implantation. Parallels between attachment of the embryo and neutrophil-endothelial interaction?** In *Gametes and Embryo Quality* Edited by: Mastrioanni L Jr. Carnforth: Parthenon publ; 1994:171-198.
117. Navot D, Bergh PA, Williams M, Garrisi GJ, Guzman I, Sandler BH, Schreiner-Engel P, Hofmann GE, Grunfeld L: **An insight into early reproductive processes through the in vivo model of ovum donation.** *J Clin Endocrinol Metab* 1991, **72**:408-414.
118. Bentin-Ley U, Sjögren A, Nilsson L, Hamberger L, Larsen JF, Horn T: **Presence of uterine pinopodes at the embryo-endometrial interface during human implantation in vitro.** *Hum Reprod* 1999, **14**:515-520.
119. Usadi RS, Murray MJ, Bagnell RC, Fritz MA, Kowalik AL, Meyer WR, Lessey BA: **Temporal and morphologic characteristics of pinopod expression across the secretory phase of the endometrial cycle in normally cycling women with proven fertility.** *Fertil Steril* 2003, **79**:970-974.
120. Hey NA, Graham RA, Seif MW, Aplin JD: **The polymorphic epithelial mucin MUC1 in human endometrium is regulated with maximal expression in the implantation phase.** *J Clin Endocrinol Metab* 1994, **78**:337-342.
121. Hey NA, Li TC, Devine P, Graham RA, Aplin JD: **MUC1 in secretory phase endometrium: expression in precisely dated biopsies and flushings from normal and recurrent miscarriage patients.** *Hum Reprod* 1995, **10**:2555-2662.
122. Aplin JD, Hey NA: **MUC1, endometrium and embryo implantation.** *Biochem Soc Transac* 1995, **23**:826-831.
123. Aplin JD, Hey NA, Graham RA: **Human endometrial MUC1 carries keratan sulphate: characteristic glycoforms in the luminal epithelium at receptivity.** *Glycobiology* 1998, **8**:269-276.
124. DeSouza MM, Surveyor GA, Price RE, Julian J, Kardon R, Zhou X, Gendler S, Hilkens J, Carson DD: **MUC1/episialin: a critical barrier in the female reproductive tract.** *J Reprod Immunol* 1999, **45**:127-158.
125. McNeer RR, Carraway CA, Fregien NL, Carraway KL: **Characterization of the expression and steroid hormone control of sialomucin complex in the rat uterus: implications for uterine receptivity.** *J Cell Physiol* 1998, **176**:110-119.
126. Bowen JA, Bazer FW, Burghardt RC: **Spatial and temporal analyses of integrin and Muc-1 expression in porcine uterine epithelium and trophectoderm in vivo.** *Biol Reprod* 1996, **55**:1098-1106.
127. Johnson GA, Bazer FW, Jaeger LA, Ka H, Garlow JE, Pfarrer C, Spencer TE, Burghardt RC: **Muc-1, integrin, and osteopontin expression during the implantation cascade in sheep.** *Biol Reprod* 2001, **65**:820-828.
128. Graham RA, Seif MW, Aplin JD, Li TC, Cooke ID, Rogers AW, Dockery P: **An endometrial factor in unexplained infertility.** *BMJ* 1990, **300**(6737):1428-1431.
129. Serle E, Aplin JD, Li TC, Warren MA, Graham RA, Seif MW, Cooke ID: **Endometrial differentiation in the peri-implantation phase of women with recurrent miscarriage: a morphological and immunohistochemical study.** *Fertil Steril* 1994, **62**:989-996.
130. Aplin JD, Meseguer M, Simon C, Ortiz ME, Croxatto H, Jones CJ: **MUC1, glycans and the cell-surface barrier to embryo implantation.** *Biochem Soc Transac* 2001, **29**(2):153-156.
131. Meseguer M, Aplin JD, Caballero-Campo P, O'Connor JE, Martin JC, Remohí J, Pellicer A, Simon C: **Human endometrial mucin MUC1 is up-regulated by progesterone and down-regulated in vitro by the human blastocyst.** *Biol Reprod* 2001, **64**:590-601.
132. Thathiah A, Blobel CP, Carson DD: **Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding.** *J Biol Chem* 2003, **278**:3386-3394.
133. Bowen JA, Burghardt RC: **Cellular mechanisms of implantation in domestic farm animals.** *Seminars Cell Devol Biol* 2000, **11**:93-104.
134. Kimber SJ, Spanswick C: **Blastocyst implantation: the adhesion cascade.** *Seminars Cell Devol Biol* 2000, **11**:77-92.
135. Domino SE, Zhang L, Gillespie PJ, Saunders TL, Lowe JB: **Deficiency of reproductive tract α (1,2) fucosylated glycans and normal fertility in mice with targeted deletions of the FUT1 or FUT2 α (1,2) fucosyltransferase locus.** *Mol Cell Biol* 2001, **21**:8336-8345.
136. Zhu ZM, Kojima N, Stroud MR, Hakomori S, Fenderson BA: **Monoclonal antibody directed to Le(y) oligosaccharide inhibits implantation in the mouse.** *Biol Reprod* 1995, **52**:903-912.
137. Wang XQ, Zhu ZM, Fenderson BA, Zeng GQ, Cao YJ, Jiang GT: **Effect of monoclonal antibodies directed to LeY on implantation in the mouse.** *Mol Hum Reprod* 1998, **4**:295-300.
138. Kimber SJ: **Carbohydrates as low affinity agents involved in initial attachment of the mammalian embryo at implantation.** In: *Early foetal growth and development* Edited by: Ward RHT, Smith SK, Donnai D. London, Royal College of Obstetricians and Gynaecologists; 1994:75-102.
139. Ravn V, Teglbaerg CS, Mandel U, Dabelsteen E: **The distribution of type-2 chain histo-blood group antigens in normal cycling human endometrium.** *Cell Tissue Res* 1992, **270**:425-433.

140. Fenderson BA: **Saccharides involved in implantation.** *TIGG* 1993, **5**:271-285.
141. Kimber SJ, Stones RE, Sidhu SS: **Glycosylation changes during differentiation of the murine uterine epithelium.** *Biochem Soc Transac* 2001, **29**:156-162.
142. Campbell S, Swann HR, Seif MW, Kimber SJ, Aplin JD: **Cell adhesion molecules on the oocyte and pre-implantation human embryo.** *Mol Hum Reprod* 1995, **1**:1571-1578.
143. Bloor DJ, Metcalfe AD, Rutherford A, Brison DR, Kimber SJ: **Expression of cell adhesion molecules during pre-implantation human development.** *Mol Human Reproduction* 2002, **8**:237-245.
144. Genbacev OD, Prakobphol A, Foulk RA, Krtolica AR, Ilic D, Singer MS, Yang ZQ, Kiessling LL, Rosen SD, Fisher SJ: **Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface.** *Science* 2003, **299**:405-408.
145. Spencer TE, Bartol FF, Bazer FW, Johnson GA, Joyce MM: **Identification and characterization of glycosylation-dependent cell adhesion molecule I-Like protein expression in the ovine uterus.** *Biol Reprod* 1999, **60**:241-250.
146. Bullard DC, Kunkel Ej, Kubo H, Hicks MJ, Lorenzo I, Doyle NA, Doerschuk CM, Ley K, Beaudet AL: **Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice.** *J Exp Med* 1996, **183**:2329-2336.
147. Robinson DS, Frenette PS, Rayburn H, Chummaskey M, Ullman-Culleré M, Wagner DD, Hynes RO: **Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment.** *Proc Natl Acad Sci USA* 1999, **96**:11452-11457.
148. Collins RG, Jung U, Ramirez M, Bullard DC, Hicks MJ, Smith W, Ley K, Beaudet AL: **Dermal and pulmonary inflammatory disease in E-selectin and P-selectin double null mice is reduced in triple-selectin-null mice.** *Blood* 2001, **98**:727-735.
149. Sutherland AE, Sanderson RD, Mayes M, Seibert M, Calarco PG, Bernfield M, Damsky CH: **Expression of syndecan, a putative low affinity fibroblast growth factor receptor, in the early mouse embryo.** *Development* 1991, **113**:339-351.
150. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberland S, Bernfield M: **Syndecan-I is required for Wnt-1-induced mammary tumorigenesis in mice.** *Nature Genetics* 2000, **25**:329-332.
151. Carson DD, Tang JP, Julian J: **Heparan sulfate proteoglycan (perlecan) expression by mouse embryos during acquisition of attachment competence.** *Devel Biol* 1993, **155**:97-106.
152. Smith SE, French MM, Julian J, Paria BC, Dey SK, Carson DD: **Expression of heparan sulfate proteoglycan (perlecan) in the mouse blastocyst is regulated during normal and delayed implantation.** *Devel Biol* 1997, **184**:38-47.
153. Costell M, Gustafsson E, Aszódi A, Mörgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fässler R: **Perlecan maintains the integrity of cartilage and some basement membranes.** *J Cell Biol* 1999, **147**:1109-1122.
154. Raab G, Kover K, Paria BC, Dey SK, Ezzell RM, Klagsbrun M: **Mouse preimplantation blastocysts adhere to cells expressing the transmembrane form of heparin-binding EGF-like growth factor.** *Development* 1996, **122**:637-645.
155. Paria BC, Elinius K, Klagsbrun M, Dey SK: **Heparin-binding EGF-like growth factor interacts with mouse blastocysts independently of ErbB1: a possible role for heparan sulfate proteoglycans and ErbB4 in blastocyst implantation.** *Development* 1999, **126**:1997-2005.
156. Chobotova K, Muchmore ME, Carver J, Yoo HJ, Manek S, Gullick WJ, Barlow DH, Mardon HJ: **The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.** *J Clin Endocrinol Metab* 2002, **87**:5769-5777.
157. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, Lee DC: **Defective valvulogenesis in HBEGF and TACE-null mice is associated with aberrant BMP signalling.** *EMBO J* 2003, **22**:2704-2716.
158. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze K, Raab G, Nanba D, Hagashiyama S, Hori M, Klagsbrun M, Mekada E: **Heparin binding EGF-like growth factor and erbB signalling is essential for heart function.** *Proc Natl Acad Sci USA* 2003, **6**:3221-3226.
159. Fukuda MN, Sato T, Nakayama J, Klier G, Mikami M, Aoki D, Nozawa S: **Trophinin and tasin, a novel cell adhesion molecule complex with potential involvement in embryo implantation.** *Genes Devel* 1995, **9**:1199-1210.
160. Suzuki N, Zara J, Sato T, Ong E, Bakheet N, Watson KL, Fukuda MN: **A cytoplasmic protein bystin, interacts with trophinin, tasin and cytokeratin.** *Proc Natl Acad Sci USA* 1998, **95**:5027-5032.
161. Nadano D, Sugihara K, Paria BC, Saburi S, Copeland NG, Gilbert DJ, Jenkins NA, Nakayama J, Fukuda MN: **Significant differences between mouse and human trophinins are revealed by their expression patterns and targeted disruption of mouse trophinin gene.** *Biol Reprod* 2002, **66**:313-321.
162. Kuno N, Kadomatsu K, Fan QW, Hagiwara M, Senda T, Mizutani S, Muramatsu T: **Female sterility in mice lacking the basigin gene, which encodes a transmembrane glycoprotein belonging to the immunoglobulin superfamily.** *FEBS Lett* 1998, **425**:191-194.
163. Xiao LJ, Chang H, Ding NZ, Ni H, Kadomatsu K, Yang ZM: **Basigin expression and hormonal regulation in mouse uterus during the peri-implantation period.** *Mol Reprod Dev* 2002, **63**:47-54.
164. Igakura T, Kadomatsu K, Kaname T, Muramatsu H, Fan QW, Miyauchi T, Toyama Y, Kuno N, Yuasa S, Takahashi M, Senda T, Taguchi O, Yamamura K, Arimura K, Muramatsu T: **A null mutation in basigin, an immunoglobulin superfamily member, indicates its important roles in peri-implantation development and spermatogenesis.** *Dev Biol* 1998, **194**:152-165.
165. Noguchi Y, Sato T, Hirata M, Hara T, Ohama K, Ito A: **Identification and characterisation of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro.** *J Clin Endocrinol Metab* 2003, **88**:6063-6072.
166. Aplin JA, Spanswick C, Behzad F, Kimber SJ, Vicovac LJ: **Integrin β 5, β 3 and α v are apically distributed in endometrial epithelium.** *Molecular Human Reproduction* 1996, **2**:527-534.
167. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA: **Structural Requirements of echistatin for the recognition of α v β 3 and α v β 1 integrins.** *J Biol Chem* 1999, **274**:37809-37814.
168. Illera MJ, Cullinan E, Gui Y, Yuan L, Beyler SA, Lessey BA: **Blockade of the α v β 3 integrin adversely affects implantation in the mouse.** *Biol Reprod* 2000, **62**:1285-1290.
169. Apparao KB, Murray MJ, Fritz MA, Meyer WR, Chambers AF, Truong PR, Lessey BA: **Osteopontin and its receptor α v β 3 integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially.** *J Clin Endocrinol Metab* 2001, **86**:4991-5000.
170. Behzad F, Seif MW, Campbell S, Aplin JD: **Expression of two isoforms of CD44 in human endometrium.** *Biol Reprod* 1994, **51**:739-747.
171. Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard JJ, Ohashi PS, Paige CJ, Gutierrez-Ramos JC, Mak TW: **CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.** *Blood* 1997, **90**:2217-2233.
172. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL: **Altered wound healing in mice lacking a functional osteopontin gene (spp1).** *J Clin Invest* 1998, **101**:1468-1478.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

